Literature DB >> 26242462

A unique aptamer-drug conjugate for targeted therapy of multiple myeloma.

J Wen1, W Tao2, S Hao1, S P Iyer3, Y Zu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26242462     DOI： 10.1038/leu.2015.216

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.

Authors:  C Tuerk; L Gold
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

2.  Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

Authors:  Michel de Weers; Yu-Tzu Tai; Michael S van der Veer; Joost M Bakker; Tom Vink; Daniëlle C H Jacobs; Lukas A Oomen; Matthias Peipp; Thomas Valerius; Jerry W Slootstra; Tuna Mutis; Wim K Bleeker; Kenneth C Anderson; Henk M Lokhorst; Jan G J van de Winkel; Paul W H I Parren
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

3.  An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform.

Authors:  Vaishali Bagalkot; Omid C Farokhzad; Robert Langer; Sangyong Jon
Journal:  Angew Chem Int Ed Engl       Date:  2006-12-11       Impact factor: 15.336

Review 4.  Discovery and development of anticancer aptamers.

Authors:  Christopher R Ireson; Lloyd R Kelland
Journal:  Mol Cancer Ther       Date:  2006-12       Impact factor: 6.261

Review 5.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

6.  Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

Authors:  W S Dalton; T M Grogan; P S Meltzer; R J Scheper; B G Durie; C W Taylor; T P Miller; S E Salmon
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

Review 7.  Antibody-drug conjugates for the treatment of cancer.

Authors:  John A Flygare; Thomas H Pillow; Paul Aristoff
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

8.  Antibody-based therapies in multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Bone Marrow Res       Date:  2011-03-02

9.  Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages.

Authors:  Olcay Boyacioglu; Christopher H Stuart; George Kulik; William H Gmeiner
Journal:  Mol Ther Nucleic Acids       Date:  2013-07-16       Impact factor: 10.183

10.  Oligonucleotide aptamers: new tools for targeted cancer therapy.

Authors:  Hongguang Sun; Xun Zhu; Patrick Y Lu; Roberto R Rosato; Wen Tan; Youli Zu
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-05       Impact factor: 10.183
View more
  15 in total

1.  Engineering of Bioinspired, Size-Controllable, Self-Degradable Cancer-Targeting DNA Nanoflowers via the Incorporation of an Artificial Sandwich Base.

Authors:  Lili Zhang; Razack Abdullah; Xiaoxiao Hu; Huarong Bai; Huanhuan Fan; Lei He; Hao Liang; Jianmei Zou; Yanlan Liu; Yang Sun; Xiaobing Zhang; Weihong Tan
Journal:  J Am Chem Soc       Date:  2019-03-05       Impact factor: 15.419

Review 2.  Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.

Authors:  Somayeh Vandghanooni; Morteza Eskandani; Jaleh Barar; Yadollah Omidi
Journal:  J Mol Med (Berl)       Date:  2018-07-28       Impact factor: 4.599

Review 3.  Aptamer-Mediated Targeted Delivery of Therapeutics: An Update.

Authors:  Silvia Catuogno; Carla L Esposito; Vittorio de Franciscis
Journal:  Pharmaceuticals (Basel)       Date:  2016-11-03

Review 4.  Current Advances in Aptamers for Cancer Diagnosis and Therapy.

Authors:  Shin-Ichiro Hori; Alberto Herrera; John J Rossi; Jiehua Zhou
Journal:  Cancers (Basel)       Date:  2018-01-03       Impact factor: 6.639

5.  Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.

Authors:  Jianguo Wen; Wenjing Tao; Suyang Hao; Youli Zu
Journal:  J Hematol Oncol       Date:  2017-06-13       Impact factor: 17.388

6.  Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy.

Authors:  Przemysław M Jurek; Konrad Zabłocki; Urszula Waśko; Maciej P Mazurek; Jacek Otlewski; Filip Jeleń
Journal:  Int J Nanomedicine       Date:  2017-04-11

7.  ssDNA Aptamer Specifically Targets and Selectively Delivers Cytotoxic Drug Doxorubicin to HepG2 Cells.

Authors:  Ge Yu; Huan Li; Shuanghui Yang; Jianguo Wen; Junqi Niu; Youli Zu
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

8.  Aptamer Internalization via Endocytosis Inducing S-Phase Arrest and Priming Maver-1 Lymphoma Cells for Cytarabine Chemotherapy.

Authors:  Huan Li; Shuanghui Yang; Ge Yu; Liangfang Shen; Jia Fan; Ling Xu; Hedong Zhang; Nianxi Zhao; Zihua Zeng; Tony Hu; Jianguo Wen; Youli Zu
Journal:  Theranostics       Date:  2017-03-06       Impact factor: 11.556

Review 9.  Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies.

Authors:  Shuanghui Yang; Huan Li; Ling Xu; Zhenhan Deng; Wei Han; Yanting Liu; Wenqi Jiang; Youli Zu
Journal:  Mol Ther Nucleic Acids       Date:  2018-09-06       Impact factor: 8.886

10.  Targeting c-met receptor tyrosine kinase by the DNA aptamer SL1 as a potential novel therapeutic option for myeloma.

Authors:  Yibin Zhang; Hongmei Gao; Weihua Zhou; Sunming Sun; Yayue Zeng; Hui Zhang; Long Liang; Xiaojuan Xiao; Jianhui Song; Mao Ye; Yujia Yang; Jingfeng Zhao; Zi Wang; Jing Liu
Journal:  J Cell Mol Med       Date:  2018-10-24       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.